Transcatheter Aortic Valve Replacement for Aortic Regurgitation--A Review

Preprint | 
10.55415/deep-2023-0045.v1
This is not the most recent version. There is anewer versionof this content available.
R Liu#
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
Guangyuan Song*
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
J Yao
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
YF Yan
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease

# contributed equally to this work, * Corresponding author

Abstract

Transcatheter aortic valve replacement (TAVR) is now a widely adopted option for patients with severe symptomatic aortic stenosis from high to low surgical risk. However, aortic regurgitation (AR) is still an “off-label” indication for TAVR, especially for patients with mild or absent leaflet calcification or aortic annulus dimensions beyond the size of bioprosthesis, which causes increased risk of dislocation. With the advance of transcatheter heart valve device, the safety and efficacy of TAVR in treating patients with severe pure native AR has gained acceptance. This review examines the current evidence and clinical practice and presents the technological advancements in the device for AR.

Download PDF
CITE
Keywords
transcatheter aortic valve implantation ;  transcatheter aortic valve replacement ;  aortic regurgitation ;  new generation devices
Subject Area
General Medical Research
Now Published
Version History
  • 07 Jul 2023 08:43 Version 1
Scores
 4
Rapid Rating Times: 1
· Level of Quality: 4
· Level of Repeatability: 3
· Level of Innovation: 4
· Level of Impact: 5

*Each rating ranges from 0-5

Rapid Rating
Your professional field is different from the direction of this article. Go Settings!
  • Level of Quality
    Is the publication of relevance for the academic community and does it provide important insights? Is the language correct and easy to understand for an academic in the field? Are the figures well displayed and captions properly described? Is the article systematically and logically organized?
    0.0
  • Level of Repeatability
    Is the hypothesis clearly formulated? Is the argumentation stringent? Are the data sound, well-controlled and statistically significant? Is the interpretation balanced and supported by the data? Are appropriate and state-of-the-art methods used?
    0.0
  • Level of Innovation
    Does the work represent a novel approach or new findings in comparison with other publications in the field?
    0.0
  • Level of Impact
    Does the work have potential huge impact to the related research area?
    0.0
Submit
Not yet Peer Reviewed
The content is available under CC BY 4.0 License CreativeCommons.org
The author(s) have declared they have no conflict of interest with regard to this content

我们使用 cookie 将您与其他用户区分开来, 并在我们的网站上为您提供更好的体验。

关闭此消息以接受 cookie 或了解如何管理您的 cookie 设置。

了解更多关于我们的隐私声明..

goTop